- Home
- TEAF vs CVRX Comparison
TEAF vs CVRX Comparison
Compare TEAF & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- CVRX
- Stock Information
- Founded
- TEAF 2017
- CVRX 2000
- Country
- TEAF United States
- CVRX United States
- Employees
- TEAF N/A
- CVRX N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TEAF Finance
- CVRX Health Care
- Exchange
- TEAF Nasdaq
- CVRX Nasdaq
- Market Cap
- TEAF 173.4M
- CVRX 185.8M
- IPO Year
- TEAF N/A
- CVRX 2021
- Fundamental
- Price
- TEAF $13.26
- CVRX $8.10
- Analyst Decision
- TEAF
- CVRX Buy
- Analyst Count
- TEAF 0
- CVRX 7
- Target Price
- TEAF N/A
- CVRX $13.67
- AVG Volume (30 Days)
- TEAF 56.1K
- CVRX 171.0K
- Earning Date
- TEAF 01-01-0001
- CVRX 10-29-2024
- Dividend Yield
- TEAF 9.20%
- CVRX N/A
- EPS Growth
- TEAF N/A
- CVRX N/A
- EPS
- TEAF N/A
- CVRX N/A
- Revenue
- TEAF N/A
- CVRX $44,393,000.00
- Revenue This Year
- TEAF N/A
- CVRX $31.01
- Revenue Next Year
- TEAF N/A
- CVRX $30.66
- P/E Ratio
- TEAF N/A
- CVRX N/A
- Revenue Growth
- TEAF N/A
- CVRX 43.94
- 52 Week Low
- TEAF $11.11
- CVRX $6.40
- 52 Week High
- TEAF $13.30
- CVRX $33.14
- Technical
- Relative Strength Index (RSI)
- TEAF 71.96
- CVRX 47.17
- Support Level
- TEAF $12.97
- CVRX $6.79
- Resistance Level
- TEAF $13.25
- CVRX $8.83
- Average True Range (ATR)
- TEAF 0.10
- CVRX 0.54
- MACD
- TEAF -0.01
- CVRX -0.02
- Stochastic Oscillator
- TEAF 100.00
- CVRX 60.37
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.